Arbutus Biopharma (ABUS) has released an update.
Arbutus Biopharma is set to present at the Jefferies London Healthcare Conference to discuss its innovative approaches in treating chronic hepatitis B virus. The company’s pipeline includes promising treatments like the RNAi therapeutic imdusiran and an oral PD-L1 inhibitor, which are in crucial stages of clinical trials.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.
